There is a constant requirement for vascular supply in solid tumors. Tumor-associated neovascularization allows the tumor cells to express their critical growth advantage. Axillary lymph node status is the most important prognostic factor in operable breast cancer, and experimental and clinical evidence suggests that the process of metastasis is also angiogenesis-dependent. Various angiogenic growth factors and cytokines induce neovascularization in tumors, namely members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) gene families. A strong correlation has been found between VEGF expression and increased tumor microvasculature, malignancy, and metastasis in breast cancer. Anti-angiogenic therapy approaches oer a new promising anti-cancer strategy and a remarkably diverse group of over 20 such drugs is currently undergoing evaluation in clinical trials. Oncogene (2000) 19, 6122 ± 6129.
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Tumor angiogenesis
During embryogenesis, the formation of new blood vessels occurs via two processes, vasculogenesis and angiogenesis. Vasculogenesis involves the de novo dierentiation of endothelial cells from mesodermderived precursors called angioblasts, which then cluster and reorganize to form capillary-like tubes (Figure 1 ) (Risau and Flamme, 1995) . Once the primary vascular plexus is formed, new capillaries form by sprouting or by splitting (intussusception) from pre-existing capillaries in the processes called sprouting and non-sprouting angiogenesis, respectively (Risau, 1997) . In adults, the growth of normal as well as neoplastic tissues also depends on angiogenesis. Anti-angiogenic therapy, a concept ®rst proposed by Judah Folkman, is a promising new anti-cancer strategy (Folkman et al., 1971) .
When a primary tumor ®rst arises proliferation of cancer cells may be balanced by apoptosis and the tumor may remain undetectable for years (Hanahan and Folkman, 1996) . A same kind of restriction of tumor growth by a high rate of apoptosis is likely to take place in clinically undetectable, micrometastatic breast cancer. Such a phenomenon, called tumor dormancy, may depend on a rate-limiting role of neovascularization (Holmgren, 1996) . The onset of neovascularization in primary tumors can be relatively sudden, described as the angiogenic switch (Hanahan and Folkman, 1996; Folkman et al., 1989) . In breast cancer, like in many other cancers, the initial period of tumor dormancy is long and tumors are commonly at the in situ stage when neovascularization appears (Brem et al., 1978) .
Recently, tumor angiogenesis has been shown to be a more complicated event (Figure 1 ). Some studies have suggested that instead of growing as avascular masses, some tumors, especially metastases, may initially grow by coopting existing host vessels (Holash et al., 1999) . This coopted host vasculature would not immediately undergo angiogenesis to support the tumor, but instead regresses, leading to secondary hypoxia, massive tumor cell loss and further to hypoxia-induced angiogenesis (Holash et al., 1999) . For example, in melanoma CNS metastasis with VEGF overexpression, the initial tumor growth is accompanied by vessel cooption, vasodilation and increase of vascular permeability, but not by angiogenesis (Robert de Waal, personal communication). Furthermore, there is also evidence of mobilization of bone marrow-derived endothelial progenitor cells (EPC) in various angiogenesis models, resulting in augmented neovascularization Peichev et al., 2000; Takahashi et al., 1999) .
Angiogenic growth factors and angiogenesis inhibitors in tumors

VEGFs
The known endothelial cell speci®c growth factors and their receptors can be classi®ed into vascular endothelial growth factor (VEGF) and angiopoietin (Ang) families (Figure 2 ).
VEGF is a major inducer of angiogenesis and it is structurally related to PlGF (placenta growth factor), VEGF-B, VEGF-C, VEGF-D and Orf virus derived VEGF (also called VEGF-E) (Ferrara and DavisSmyth, 1997; Erikson and Alitalo, 1999; Persico et al., 1999; Achen et al., 1998; Ogawa et al., 1998; Meyer et al., 1999) . Loss of even a single VEGF allele results in embryonic lethality, suggesting that VEGF levels are critical during embryonic angiogenesis (Ferrara et al., 1996; Carmeliet et al., 1996) . There are to date three known receptor tyrosine kinase that bind VEGFs (VEGFR-1, VEGFR-2 and VEGFR-3) (Neufeld et al., 1999; Veikkola et al., 2000; Aprelikova et al., 1992) . In adults, VEGFR-1 and VEGFR-2 are expressed mainly in the blood vascular endothelium, while VEGFR-3 is mostly restricted to the lymphatic Figure 1 Schematic illustration of vasculogenic and angiogenic processes in developing embryos and in tumors. In vasculogenesis, mesodermal cells ®rst dierentiate into hemangioblasts, whereafter endoderm-mesoderm interactions are required for further blood island dierentiation (Risau and Flamme, 1995) . Endothelial cell precursors (angioblasts) and hematopoietic cell precursors share several surface markers, and they are thought to be derived from the hemangioblasts. After the primary capillary plexus has been formed, new vessels are generated via angiogenesis (Risau, 1997) . During sprouting angiogenesis, endothelial cells degrade the underlying basement membrane, migrate, proliferate and reassemble into tubes. In non-sprouting angiogenesis, new vessels are formed by intussusceptive growth or the existing vessels increase in size through intercolated growth. The formed vasculature is further remodeled into a more mature treelike hierarchy containing vessels of dierent sizes when excess branches are pruned, some vessels regress and others fuse to form larger vessels. The vessels further dierentiate by recruitment of pericytes and smooth muscle cells. Formation of the extracellular matrix (ECM) and particularly the basal lamina gives support to the vessels. Arteriovenous dierentiation is regulated by the ephrins and their Eph receptors (Holder and Klein, 1999; Adams et al., 1999; Wang et al., 1998) . A widely accepted theory suggests that during the embryonic period lymphatic vessels are generated by sprouting from central veins, and at least in avian species there may exist a separate lymphatic endothelial cell precursor or lymphangioblast (J Wilting, personal communication) . The stages at which the inactivation of the endothelial speci®c receptor tyrosine kinases is lethal on the basis of gene targeting studies are marked on the left. In tumors, the onset of neovascularization is described as the angiogenic switch (Hanahan and Folkman, 1996; Folkman et al., 1989) . Vasculogenesis has also been shown to take place in some degree via angioblast homing in angiogenic tumor vessels Peichev et al., 2000; Takashi et al., 1999) . In addition to sprouting angiogenesis, especially metastases may initially grow by coopting existing host vessels (Holash et al., 1999) . endothelium (Neufeld et al., 1999; Kaipainen et al., 1995) . Neuropilin-1, originally discovered as a neuronal guidance molecule for axons, has recently been shown to function as a co-receptor for the VEGF165 isoform, P1GF-2, VEGF-B and Orf virus VEGF (Wise et al., 1999; Soker et al., 1998; Migdal et al., 1998; Makinen et al., 1999) . VEGF mRNA and protein are upregulated by hypoxia and VEGF mRNA is often elevated near areas of tumor necrosis (Plate et al., 1992; Shweiki et al., 1992) . In hypoxic tissues the hypoxia inducible factor-1 (HIF-1) has a central role in inducing the transcription of genes that are involved in glycolysis and angiogenesis, including VEGF (Gleadle and Ratclie, 1998). Tumor hypoxia and locally increased VEGF concentrations also upregulate VEGFR-1 and VEGFR-2 (Kremer et al., 1997) .
The VEGF expression is stimulated by oncogenes, for example by members of the Ras and erbB families Viloria-Petit et al., 1997) , whereas the von Hippel-Lindau (vHL) tumor suppressor gene product has been shown to inhibit the production of VEGF (Siemeister et al., 1996; Gnarra et al., 1996) , primarily by increasing HIF-1 degradation via the ubiquitin ligase system (Maxwell et al., 1999) . VEGF expression has also been shown to be regulated by estradiol in human breast cancer cells and in a recently published study a functional estrogen response element was identi®ed in the regulatory region of the VEGF gene (Hyder et al., 2000) . These kinds of ®ndings form a link between basic genetic cancer research, oncogenes, tumor suppressor genes and the regulation of tumor angiogenesis.
While VEGF acts only on blood vessels, another member of the VEGF family, VEGF-C, can also stimulate the growth of lymphatic vessels, a process called lymphangiogenesis. VEGF-C mRNA is not induced by hypoxia and it is dierentially regulated than VEGF (Enholm et al., 1997) . Overexpression of VEGF-C under a basal keratin promoter in transgenic mice induced a hyperplastic lymphatic vessel network in the skin of adult mice . Partially processed forms of VEGF-C are able to bind and activate VEGFR-3, whereas its proteolytically processed forms are potent stimulators of both VEGFR-2 and VEGFR-3 . Presumably through its interaction with VEGFR-2, VEGF-C shares the major functions of VEGF, including induction of angiogenesis and vascular permeability (Joukov et al., 1998) . The expression of VEGFR-3 becomes restricted mainly to lymphatic endothelium during development (Kaipainen et al., 1995; Kukk et al., 1996) . In embryos, targeted disruption of the VEGFR-3 gene leads to a failure of remodeling of the primary vascular network, and death after embryonic day 9.5 (Dumont et al., 1998) . This indicates that VEGFR-3 has an essential role in the development of the embryonic vasculature before the emergence of lymphatic vessels. In tumors VEGFR-3 is also upregulated in angiogenic blood vessels (Valtola et al., 1999; Saaristo et al., 2000) .
Angiopoietins
Like VEGFs, angiopoietins have also been shown to play a role in the formation of the blood vascular system. To date there are four known angiopoietins, which all bind to the Tie-2 receptor, mediating vessel stabilization signals, whereas the Tie-1 receptor has so far no known ligand (Figure 2) Maisonpierre et al., 1997; Kim et al., 1999; Valenzuela et al., 1999) . The phenotypes of Tie-2 and Ang-1 de®cient mice suggest a role for this ligand ± receptor system in maintaining communication between endothelial cells and the surrounding mesenchyme, in order to establish stable cellular and biochemical interactions between endothelial cells and pericytes/ smooth muscle cells (Dumont et al., 1994; Puri et al., 1995; Suri et al., 1997) . On the other hand, overexpression of Ang-1 in the skin of transgenic mice demonstrated that Ang-1 can induce a hypervascular phenotype with increased vessel size, but not amount. Ang-1 can also reduce vascular leakage even in the presence of excess VEGF (Thurston et al., 1999) . Interestingly, the expression of Ang-2, an antagonist of the Tie-2 receptor, has been mainly detected at sites of active angiogenesis, including tumors Holash et al., 1999) , suggesting that it plays a crucial role in destabilizing quiescent adult vessels, and thus it seems to be involved in the initiation of vascular remodeling.
Other angiogenic growth factors and angiogenesis inhibitors
In addition to endothelial cell speci®c growth factors, there is also a wide range of other less speci®c angiogenic growth factors, including basic ®broblast growth factor (bFGF) and transforming growth factorb (TGF-b) (Friesel and Maciag, 1995; Roberts and Sporn, 1989) . Recently, Eph receptor tyrosine kinases and their cell-surface-bound ephrin ligands were found to have a role in de®ning boundaries between arterial Figure 2 VEGFs and angiopoietins, their receptor binding speci®city, and some of their endothelial eects. Neuropilin (NRP-1) functions as a co-receptor for the VEGF165 isoform, PlGF-2, VEGF-B and VEGF-E. Ang-1 and Ang-4 are stimulatory ligands for Tie-2, whereas Ang-2 and Ang-3 are inhibitory and venous vascular domains (Holder and Klein, 1999; Adams et al., 1999; Wang et al., 1998) . Ligands of the Ephrin B family were also found to induce capillary sprouting in vitro (Adams et al., 1999) . Among nontyrosine kinase receptors, a recently characterized member of the Delta family of Notch ligands, Dll4 is expressed speci®cally in vascular endothelial cells, suggesting a role in the control of endothelial cell biology (Shutter et al., 2000) .
A large and structurally diverse group of endogenous angiogenesis inhibitors has also been discovered, including thrombospondin-1 (Tolsma et al., 1993) , interferon-a/b (Dvorak and Gresser, 1989), angiostatin (O'Reilly et al., 1994) , endostatin (O'Reilly et al., 1997) and anti-thrombin III (O'Reilly et al., 1999) . Some of these are fragments of proteins, that are either components of the extracellular matrix (ECM) or of enzymes of the blood clotting pathways. The angiogenic switch in tumors is currently thought to be caused by a shift in the net balance of positively and negatively acting angiogenic mediators, angiogenic growth factors and angiogenesis inhibitors, respectively. The mechanisms underlying this shift of balance remain incompletely understood. Interestingly, loss of wild type p53 gene function has been shown to cause loss of thrombospondin-1 expression (Dameron et al., 1994) . Thus, some oncogenes and tumor-suppressor genes contribute to the angiogenic switch by causing up-or down-regulation of endogenous angiogenesis inhibitors or pro-angiogenic growth factors Hanahan and Folkman, 1996) . On the other hand, the control of bioavailability of angiogenic activators and inhibitors also has a role in the regulation of the angiogenic switch. A variety of proteases can release TGF-b or bFGF stored in the extracellular matrix Whitelock et al., 1996) , whereas proteolytic cleavage of plasmin results in the formation of the inhibitor, angiostatin (Gately et al., 1997) .
Primary breast carcinomas, like many other human tumors, are known to produce many dierent angiogenic growth factors. In addition to tumor cells, also stromal cells such as macrophages, lymphocytes, natural killer cells, ®broblasts and endothelial cells are capable of releasing a number of pro-or antiangiogenic growth factors (Senger, 1996) . However, although inhibition of a variety of angiogenic growth factors may decrease tumor growth, VEGF and its receptors constitute the most promising target for antiangiogenic therapy. VEGF-negative embryonic stem cells and tumor cells grow poorly as tumors in syngeneic mice (Grunstein et al., 1999; Ferrara et al., 1996) . Inhibition of VEGF signaling either by dominant-negative VEGFR-2, soluble forms of the VEGFR-1 or anti-VEGF antibody decreases tumor growth in experimental models (Millauer et al., 1994; Kong et al., 1998; Kim et al., 1993) . VEGF mRNA is known to be upregulated in most human tumors and expression of VEGF and its receptors correlates with the degree of vascularization of many experimental and clinical tumors (Ferrara and Davis-Smyth, 1997) . Loss of VEGF expression also can lead to tumor regression Benjamin and Keshet, 1997) . In a comprehensive study of primary human breast cancer, an independent correlation between VEGF expression, microvessel density and clinical prognosis has been found (Gasparini et al., 1997) .
Tumor metastasis
Angiogenesis and the vascular density of tumors have been shown to be associated with tumor metastasis. Several studies since Weidner's ®rst report in 1991 reveal that the higher the microvessel count is in areas of highest vessel density, the lower is the rate overall survival of the tumor patients (Weidner et al., 1991) . Neovascularization can be quanti®ed in histological sections of human tumors by quantifying vessels stained for endothelial cell markers. This method revealed a signi®cant direct correlation between the highest microvessel density in histological sections of invasive breast cancer and occurrence of metastases (Weidner et al., 1991) . For a tumor cell to metastasize it must pass through several barriers and ®nally be able to survive and grow in the target tissue. First tumor cells must enter the vasculature in the primary tumor. VEGF and bFGF, secreted by the tumor cells, induce the expression of plasminogen activator and collagenases, contributing to the degradation of basement membranes (Kalebic et al., 1983; Nagy et al., 1989) . In addition, proliferating tumor capillaries with fragmented and leaky basement membranes are easily penetrated by tumor cells. In fact, a considerable percentage of tumor blood¯ow is in direct contact with tumor cells (Hashizume et al., 2000) . After overcoming the ®rst vascular barrier tumor cells have to survive the circulation, attach to the microvasculature of the target organ, exit from this vasculature (usually through postcapillary venular endothelium) and survive in the target tissue (Nicolson, 1988) . Furthermore, in order to form macrometastases, micrometastatic cells must also be able to induce angiogenesis in their new target tissue.
While angiogenesis is required for tumor growth, active lymphangiogenesis has not been detected within tumors. During wound healing angiogenesis, however, transient lymphangiogenesis is detected in the developing granulation tissue (Paavonen et al., 2000) . Because the metastatic spread of breast carcinomas and many other tumors has been suggested to occur via the lymphatic vessels, the regulation of their function is crucial for understanding tumor metastasis. According to a recent analysis, functional lymphatic vessels are often absent from the interior of solid tumors, possibly due to collapse of the vessels by the interstitial pressure induced by the growing cancer cells and the leaky tumor blood vessels (Leu et al., 2000) . Functional, enlarged lymphatics were, however, detected in the tumor periphery.
VEGF-C is a growth factor for both lymphatic and blood vessels, and the expression of its speci®c receptor VEGFR-3 becomes restricted mainly to the lymphatic endothelium during development (Kaipainen et al., 1995; Kukk et al., 1996) . Recently, expression of VEGF-C was detected in breast carcinoma cells and its receptors were expressed in the vasculature of breast carcinomas (Figure 3) (Valtola et al., 1999) . Several recent reports have suggested a correlation between VEGF-C expression and lymphatic metastasis in tumors (Ohta et al., 1999; Tsurusaki et al., 1999; Yonemura et al., 1999) . To study the role of VEGF-C in tumor metastasis, mice overexpressing VEGF-C under the rat insulin promoter (Rip) were produced and mated with mice that spontaneously develop pancreatic beta cell tumors as a consequence of SV40 large T antigen expression driven by the same promoter (Mandriota et al., unpublished data). The tumors of such Rip1Tag2 mice are capable of local invasion, but do not induce lymphangiogenesis nor the formation of metastases (Hanahan, 1985) . However, in the double transgenic model, the VEGF-C induced excessive lymphangiogenesis around the pancreatic beta-cell tumors resulted in metastatic spread to pancreatic and regional lymph nodes (Mandriota et al., unpublished data) . This data suggests that, even though the tumor itself lacks functional lymphatic vessels, the VEGF-C overexpression induced increase of peritumoral lymphatics makes the lymphatic vessels more accessible to the metastases.
Inhibition of angiogenesis
Several strategies have been used to generate angiogenesis inhibitors suitable for clinical trials. Angiogenesis inhibition strategies have many advantages when they are compared to other approaches of anti-cancer therapy. Unlike most tumor cells, endothelial cells are readily accessible from the blood circulation and as genetically stable cells they are not likely to develop resistance to cytostatic therapy (Kerbel, 1997) . Furthermore, most endothelial cells in adult tissues have a dierentiated phenotype with very slow proliferation rates, compared to the actively proliferating and less dierentiated endothelial cells of angiogenic tumor vessels (Folkman, 1995) . Over 20 anti-angiogenic drugs are currently undergoing evaluation in phase I, II or III clinical trials. Anti-angiogenic drugs are not going to be curative in the usual sense, but instead they are either going to prevent the expansion of tumor mass, i.e. to cause tumordormancy, or even sustained regression of the tumor. The molecular mechanisms of angiogenesis seem to vary in dierent sites and for that reason angiogenesis inhibitors are likely to have variable eects in dierent tumors. The need to use anti-angiogenic drugs chronically has raised concerns about their delayed toxic side eects and eects on physiological angiogenesis in humans. Negative control using anti-VEGF-C antibodies blocked with a 10-fold molar excess of the VEGF-C protein gave no staining of the carcinoma cells (b). VEGFR-2 and VEGFR-3 staining are shown in (c) and (d), respectively. Staining for the blood vascular endothelium speci®c PAL-E and the proliferation marker Ki-67 showed that these vessels contain proliferating endothelial cells (data not shown, for reference, see Valtola et al. 1999) Angiogenesis and breast cancer A Saaristo et al
Whether tumors express predominantly a single or multiple angiogenic factors is an important consideration. If angiogenesis of a tumor is primarily initiated by one growth factor, speci®c blocking of that factor is likely to be sucient. In contrast, if multiple factors are involved, alternative strategies of anti-angiogenic therapy, such as relatively broad-spectrum tyrosine kinase inhibitors, will probably be required. Inhibition of VEGF or its receptor alone seems therapeutically sucient in a wide variety of tumor models (Kong et al., 1998; Brekken et al., 1998; Goldman et al., 1998; Presta et al., 1997) . However, whether tumors are able to activate other angiogenic pathways during monotherapy remains to be seen.
Some reports have also emphasized the potential anti-angiogenic eect of various cytotoxic drugs, radiation therapy and hormonal ablation therapeutic procedures (Kerbel, 1991; Denekamp, 1993) . Furthermore, in contrast to the tumor cells, endothelial cells are not likely to acquire resistance to cytotoxic therapy. In a recently published study, a low-dose chemotherapy schedule suppressed the growth of a drug resistant breast cancer cell line threefold more eciently than the conventional high dose schedule (Browder et al., 2000; Klement et al., 2000) . However, whether endothelial cells really are the key mediators of these responses and whether they can develop resistance to chemotherapy is not yet clear. Combination of low dose chemotherapy and dierent kinds of angiogenesis inhibitors is now widely used in a variety of clinical trials.
Vascular targeting
In contrast to the normal blood vessels, tumor vessels are characteristically immature, poorly functioning and leaky undierentiated endothelial channels (Hashizume et al., 2000) . A prominent molecular dierence to normal blood vessels is the expression of certain integrins in tumor vasculature that is undergoing angiogenesis (Brooks et al., 1994a,b) . Integrins have also been shown to potentiate VEGF function in cell survival (see Ruoslahti, 1999) and VEGF has been found to upregulate cell adhesion molecules in vitro (Melder et al., 1996) and in vivo (Detmar et al., 1998) . Various antagonists of avb3 or a5b1 integrins are capable of inhibiting tumor angiogenesis (Kim et al., 2000) .
The vasculature of individual normal tissues is also highly specialized. It follows that tumor metastasis into preferred organs is likely to be dependent on adhesive interactions between tumor cells and organspeci®c endothelial markers Ruoslahti, 1999) . The tissue speci®c vascular markers provide new opportunities for the targeting of therapeutic compounds, such as genes and drugs, in order to avoid unwanted toxicity towards other tissues. For example, coupling of doxorubicin to an av integrin-binding RGD peptide or NGF peptide yielded compounds that homed speci®cally to tumors and thus had reduced side eects (Arap et al., 1998a) . Interestingly, some of such tumor homing peptides have a potential of inhibiting the tumor cell invasion (Koivunen et al., 1999) .
Perspectives
Most of the experimental angiogenesis studies so far have been done in rapidly growing, transplantable mouse tumor models. The responses of these kinds of tumors to anti-angiogenic therapy are likely to be dierent from the more slowly growing, spontaneous tumors, such as most human tumors. Also, the evaluation of the eects of dierent therapies on metastases growing in a particular organ is needed, since there appear to be organ-speci®c endothelial markers and the vasculature of the tumor is likely to dier depending on the site of growth (Arap et al., 1998b; Pegram et al., 1998) .
Most anti-angiogenic drugs now in clinical trials are employed at low doses over months to years. For example, the eect of interferon alfa-2a administration in hemangiomas or giant cell tumors is not initially detected for several months (Kaban et al., 1999) . Longterm treatment with speci®c tyrosine kinase inhibitors provides one of the most promising approaches to antiangiogenic and anti-tumor therapy. Whether such long lasting therapies cause some delayed side eects remains to be seen. Moreover, new imaging methods and markers to monitor vascular function and therapeutic responses are needed.
Although angiogenesis research has traditionally been done in cancer research laboratories, therapeutic angiogenesis approaches are a new exciting frontier of cardiovascular medicine as well. Promoting the formation of new collateral vessels in the ischemic leg or myocardium has been tested in animal models. Several angiogenic molecules, including VEGF and bFGF, have been used either as recombinant protein or via gene transfer, as naked DNA or in e.g. adenoviral vectors (Isner et al., 1996; Yla-Herttuala et al., 1997) . Whether these kind of proangiogenic therapies are going to enhance the growth of spontaneous, dormant tumors, needs to be studied.
VEGF-C was the ®rst growth factor found to be lymphangiogenic and recently, a missense mutation of its receptor VEGFR-3 was found to be linked to primary human lymphedema . Secondary lymphedema is a typical problem in post-operative breast cancer patients after evacuation of axillary lymph nodes leading to considerable morbidity and the possible development of angiosarcoma (Witte et al., 1997) . Understanding the function of normal lymphatic vessels and mechanisms of lymphangiogenesis might also oer new ways of treating patients with lymphatic dysfunction. On the other hand, blocking of VEGFR-3 signaling, for example by speci®c antibodies or soluble receptors, might also be tried for the inhibition of the growth and permeability of the lymphatic vessels in order to inhibit the formation of tumor metastases.
